Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Myelodysplastic Syndromes 2Rhabdomyosarcoma 1Primary Myelofibrosis 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2Nivolumab 2LY3023414 2imetelstat 1fludarabine 1cixutumumab 1cabozantinib 1Whole-Body Irradiation 1Tacrolimus 1Pharmacogenomic Variants 1Oxaliplatin 1Neoadjuvant Therapy 1Melphalan 1MLN 8237 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hepatoblastoma × GRN163L peptide × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡